Beta Bionics Unveils Its Tubeless Pump Called "Mint"

At this year’s ADA Scientific Sessions, Beta Bionics—the company behind the iLet Bionic Pancreas—offered a first glimpse at its upcoming tubeless insulin pump. Dubbed “Mint”, the semi-reusable device was revealed during an investor meeting, and despite only being in development, it’s already stirring up real excitement in the diabetes tech space.

Why “Mint”? Well, besides being a one-syllable, punchy name (which I love), the pump’s compact design and clean aesthetics look... dare I say, fresh. And it’s a bold move for Beta Bionics as they join Insulet’s Omnipod in the tubeless arena, while Tandem and Medtronic continue working on their own versions. I’ll share what we know so far about the device here and if you’d like to hear more about what I think of each feature and how they compare to other tech in development, read my exclusive deep dive on Mint.

Here’s what Beta Bionics has shared about the Mint pump:

• 3-day wear time, plus a 12-hour grace period

• 200 units of insulin capacity

• Controlled via smartphone—will support both iOS and Android

• Semi-reusable & no charging: disposable batteries and reusable “brains”

• Automatic pairing—no reconnecting to a phone during site changes!

• Smallest cannula of any tubeless pump: a 4.5mm steel needle

• Manual button triggers insertion

The hardware design is where this pump really sets itself apart. Mint uses a two-part design: the adhesive patch plus disposable base (containing the batteries and insulin) and the reusable “brains” (likely the controller and communication tech). Users just snap them together, place the pump on the arm, and press a single on-body button to insert the needle. No secondary device, no Bluetooth pairing, and no need to charge it—ever. That makes for an incredibly streamlined experience—especially compared to the disruptions users sometimes face with existing tubeless options. Unfortunately, there is no on-board bolus button which is a feature I loved when I tried out Tandem Mobi. Let us know what you think of a bolus button in the poll below.

Beta Bionics says the pump should arrive by the end of 2027, and its clean user experience suggests they’re aiming for a device that’s not just functional, but simple to use. That's also consistent with the company's broader vision: combining automated insulin delivery with low-friction usability. Beta Bionics’ iLet uses a unique algorithm that only needs one setting to get started: the user’s weight. It eliminates the need for carb counting too—users simply indicate the size of their meals to receive boluses.

And with Beta Bionics already working with Abbott to integrate its upcoming dual glucose-ketone sensor, we can expect the Mint to play a role in a much more robust closed-loop system down the road—possibly supporting features like sick day prediction and real-time ketone alerts.

As the tubeless market heats up, Omnipod will face more pressure to share its roadmap for a next-gen system-especially now that rivals are catching up. If you haven't already, check out my video on what I want to see on Omnipod's next-gen pump.

Beta Bionics' upcoming Mint patch pump marks an exciting advancement in the tubeless diabetes tech space. For many people—myself included—tubeless is the only type of pump we’re open to using, and this new option could attract a whole wave of users who’ve been waiting for a device like this from Beta Bionics.

Likewise, Tandem and Medtronic are now under pressure to accelerate development of their own tubeless devices. We've covered both efforts-read up on Tandem Mobi's evolving strategy, and our breakdown of Medtronic's upcoming tubeless patch pump.

If you’re finding value in our content, consider joining Diabetech All Access—our premium membership that unlocks our exclusive coverage of Mint, supports our independent diabetes tech journalism, and helps keep this site going strong.